[
    {
        "symbol": "SGEN",
        "publishedDate": "2022-07-05 10:06:27",
        "title": "Top 5 Nasdaq Stocks Flying High Amid Index's Bloodbath in 1H",
        "image": "https://images.financialmodelingprep.com/news/top-5-nasdaq-stocks-flying-high-amid-indexs-bloodbath-20220705.jpg",
        "site": "zacks.com",
        "text": "We have narrowed our search to five Nasdaq Composite listed stocks that have witnessed a double-digit rally year to date. These are: AEP, AZPN, SGEN, DLTR and TMUS.",
        "url": "https://www.zacks.com/stock/news/1947933/top-5-nasdaq-stocks-flying-high-amid-index-s-bloodbath-in-1h"
    },
    {
        "symbol": "SGEN",
        "publishedDate": "2022-07-04 09:30:00",
        "title": "Oncology ABCs: A Small-Cap Biopharma Prospectus Series",
        "image": "https://images.financialmodelingprep.com/news/oncology-abcs-a-smallcap-biopharma-prospectus-series-20220704.jpg",
        "site": "seekingalpha.com",
        "text": "Oncology remains the fastest growing pharma segment, where innovation is largely driven by emerging small companies. The global oncology market is estimated at c US$175\u2013180bn and is anticipated to more than double from current levels within the next seven years to address the rising incidence rates.",
        "url": "https://seekingalpha.com/article/4521648-oncology-small-cap-biopharma-prospectus-series"
    },
    {
        "symbol": "SGEN",
        "publishedDate": "2022-07-04 09:22:09",
        "title": "A Buyout-Driven Pair Trade: Buy Aurinia, Sell Merck (Or Seagen If You Must)",
        "image": "https://images.financialmodelingprep.com/news/a-buyoutdriven-pair-trade-buy-aurinia-sell-merck-or-20220704.jpg",
        "site": "seekingalpha.com",
        "text": "The most recent two hottest potatoes in the biotech arena are Aurinia Pharmaceuticals and Seagen. While the latter is mostly/recently associated with an upcoming Merck buyout, the former has been associated with many big pharma names.",
        "url": "https://seekingalpha.com/article/4521644-buyout-pair-trade-buy-aurinia-sell-merck-seagen"
    },
    {
        "symbol": "SGEN",
        "publishedDate": "2022-07-02 06:35:00",
        "title": "Seagen Announces Results from Pivotal MOUNTAINEER Trial Demonstrating Clinically Meaningful Antitumor Activity of TUKYSA\u00ae (tucatinib) in Combination with Trastuzumab in Previously Treated HER2-Positive Metastatic Colorectal Cancer",
        "image": "https://images.financialmodelingprep.com/news/seagen-announces-results-from-pivotal-mountaineer-trial-demonstrating-clinically-20220702.jpg",
        "site": "businesswire.com",
        "text": "BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced full results from the pivotal phase 2 MOUNTAINEER trial, which showed TUKYSA\u00ae (tucatinib) in combination with trastuzumab was well-tolerated with durable responses in patients with previously treated HER2-positive metastatic colorectal cancer (mCRC). These late-breaking data were presented in an oral session at the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer on July 2 in Barcelo",
        "url": "https://www.businesswire.com/news/home/20220702005001/en/Seagen-Announces-Results-from-Pivotal-MOUNTAINEER-Trial-Demonstrating-Clinically-Meaningful-Antitumor-Activity-of-TUKYSA%C2%AE-tucatinib-in-Combination-with-Trastuzumab-in-Previously-Treated-HER2-Positive-Metastatic-Colorectal-Cancer/"
    },
    {
        "symbol": "SGEN",
        "publishedDate": "2023-02-03 15:48:08",
        "title": "4 Biotech Stocks Set to Outpace Q4 Earnings Estimates",
        "image": "https://images.financialmodelingprep.com/news/4-biotech-stocks-set-to-outpace-q4-earnings-estimates-20230203.jpg",
        "site": "zacks.com",
        "text": "Let us look at some biotech stocks, ALLO, EDIT, NTLA and SGEN that are poised to beat on fourth-quarter earnings.",
        "url": "https://www.zacks.com/stock/news/2049779/4-biotech-stocks-set-to-outpace-q4-earnings-estimates"
    },
    {
        "symbol": "SGEN",
        "publishedDate": "2023-03-13 11:58:15",
        "title": "Pfizer to pay $43B for Seagen, boosting cancer drug portfolio",
        "image": "https://images.financialmodelingprep.com/news/pfizer-to-pay-43b-for-seagen-boosting-cancer-drug-20230313.jpg",
        "site": "nypost.com",
        "text": "The latest deal comes as\u00a0Pfizer\u00a0seeks to mitigate an anticipated $17 billion hit to revenue by 2030 from patent expirations for top drugs and decline in demand for its COVID products.",
        "url": "https://nypost.com/2023/03/13/pfizer-looks-past-covid-with-43b-deal-for-seagen/"
    },
    {
        "symbol": "SGEN",
        "publishedDate": "2023-03-13 11:48:27",
        "title": "Why Seagen Stock Is Soaring Today",
        "image": "https://images.financialmodelingprep.com/news/why-seagen-stock-is-soaring-today-20230313.jpg",
        "site": "fool.com",
        "text": "Pfizer plans to acquire Seagen for around $43 billion. Investors appear to have already been betting the deal would happen after several weeks of rumors about a potential buyout.",
        "url": "https://www.fool.com/investing/2023/03/13/why-seagen-stock-is-soaring-today/"
    },
    {
        "symbol": "SGEN",
        "publishedDate": "2023-03-13 11:41:30",
        "title": "Seagen Stock Boosted on Billion-Dollar Buyout",
        "image": "https://images.financialmodelingprep.com/news/seagen-stock-boosted-on-billiondollar-buyout-20230313.jpg",
        "site": "schaeffersresearch.com",
        "text": "Seagen Inc (NASDAQ:SGEN) stock is soaring today, after news that Pfizer (PFE) is acquiring the company for roughly $43 billion, expanding its access to cancer treatment.",
        "url": "https://www.schaeffersresearch.com/content/news/2023/03/13/seagen-stock-boosted-on-billion-dollar-buyout"
    },
    {
        "symbol": "SGEN",
        "publishedDate": "2023-03-13 11:17:00",
        "title": "Regional banks pace decliners, as biotech deals lift Seagen and Provention Bio",
        "image": "https://images.financialmodelingprep.com/news/regional-banks-pace-decliners-as-biotech-deals-lift-seagen-20230313.jpg",
        "site": "marketwatch.com",
        "text": "Here are some of the biggest movers on Monday with banks firmly in focus after federal regulators stepped into protect deposits at fallen bank SVB.",
        "url": "https://www.marketwatch.com/story/regional-banks-pace-decliners-as-biotech-deals-lift-seagen-and-provention-bio-78a5d161"
    },
    {
        "symbol": "SGEN",
        "publishedDate": "2023-03-13 11:15:31",
        "title": "SGEN Stock Alert: Pfizer Buys Seagen in GIANT $43 Billion Deal",
        "image": "https://images.financialmodelingprep.com/news/sgen-stock-alert-pfizer-buys-seagen-in-giant-43-20230313.jpg",
        "site": "investorplace.com",
        "text": "Seagen (NASDAQ: SGEN ) stock is taking off on Monday as investors react to an acquisition deal with Pfizer (NYSE: PFE ). Pfizer is acquiring Seagen for $43 billion in cash.",
        "url": "https://investorplace.com/2023/03/sgen-stock-alert-pfizer-buys-seagen-in-giant-43-billion-deal/"
    },
    {
        "symbol": "SGEN",
        "publishedDate": "2023-03-13 09:17:57",
        "title": "Pfizer Officially Nabs Seagen For $43 Billion; Provention Soars On Sanofi Deal",
        "image": "https://images.financialmodelingprep.com/news/pfizer-officially-nabs-seagen-for-43-billion-provention-soars-20230313.jpg",
        "site": "investors.com",
        "text": "Pfizer will buy Seagen for roughly $43 billion, and Sanofi will buy Provention for $2.9 billion. SGEN stock and PRVB stock soared.",
        "url": "https://www.investors.com/news/technology/sgen-stock-prvb-stock-rocket-after-nabbing-takeover-deals/"
    },
    {
        "symbol": "SGEN",
        "publishedDate": "2023-03-13 07:04:00",
        "title": "Pfizer to purchase Seagen in $43 billion all-cash deal, cancer biotech's stock pops 20%",
        "image": "https://images.financialmodelingprep.com/news/pfizer-to-purchase-seagen-in-43-billion-allcash-deal-20230313.jpg",
        "site": "marketwatch.com",
        "text": "Pfizer Inc. PFE, -0.18% plans to acquire cancer biotechnology company Seagen Inc. SGEN, -0.59% in a deal with a $43 billion enterprise value, the companies announced Monday morning. Pfizer intends to pay $229 a share in cash for Seagen, which discovers and develops cancer drugs.",
        "url": "https://www.marketwatch.com/story/pfizer-to-purchase-seagen-in-43-billion-all-cash-deal-cancer-biotechs-stock-pops-20-1792912e"
    },
    {
        "symbol": "SGEN",
        "publishedDate": "2023-03-13 06:45:00",
        "title": "Pfizer Invests $43 Billion to Battle Cancer",
        "image": "https://images.financialmodelingprep.com/news/pfizer-invests-43-billion-to-battle-cancer-20230313.jpg",
        "site": "businesswire.com",
        "text": "NEW YORK & BOTHELL, Wash.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of $43 billion. The Boards of Directors of both companies have unanimously approved the transaction.",
        "url": "https://www.businesswire.com/news/home/20230313005389/en/Pfizer-Invests-43-Billion-to-Battle-Cancer/"
    },
    {
        "symbol": "SGEN",
        "publishedDate": "2023-03-09 18:30:00",
        "title": "Astellas and Seagen Announce China's National Medical Products Administration Accepts Biologics License Application for Enfortumab Vedotin in Certain Patients with Locally Advanced or Metastatic Urothelial Cancer",
        "image": "https://images.financialmodelingprep.com/news/astellas-and-seagen-announce-chinas-national-medical-products-administration-20230309.jpg",
        "site": "prnewswire.com",
        "text": "\u2013 Clinical data submitted are consistent with global data and support enfortumab vedotin as a platinum-free option in patients with locally advanced or metastatic urothelial cancer who received prior treatment with a PD-1/L1 inhibitor and platinum-based chemotherapy \u2013 TOKYO and BOTHELL, Wash. , March 9, 2023 /PRNewswire/ --\u00a0Astellas Pharma Inc. (TSE:4503, President and CEO:\u00a0Kenji Yasukawa, Ph.D.",
        "url": "https://www.prnewswire.com/news-releases/astellas-and-seagen-announce-chinas-national-medical-products-administration-accepts-biologics-license-application-for-enfortumab-vedotin-in-certain-patients-with-locally-advanced-or-metastatic-urothelial-cancer-301768359.html"
    },
    {
        "symbol": "SGEN",
        "publishedDate": "2023-03-08 08:00:02",
        "title": "Hot Stocks And Hot Wings Serve Up Spicy Breakouts And Buy Zones",
        "image": "https://images.financialmodelingprep.com/news/hot-stocks-and-hot-wings-serve-up-spicy-breakouts-20230308.jpg",
        "site": "investors.com",
        "text": "As the market indexes fight for support, ANET, WING, BKNG, CDNS, PANW and more land a spot on the IBD Breakout Stocks Index. The post Hot Stocks And Hot Wings Serve Up Spicy Breakouts And Buy Zones appeared first on Investor's Business Daily.",
        "url": "https://www.investors.com/research/breakout-stocks-technical-analysis/anet-wing-lead-hot-stocks-serving-up-spicy-breakouts-and-buy-zones/"
    },
    {
        "symbol": "SGEN",
        "publishedDate": "2023-03-07 22:54:51",
        "title": "The 5 Best and Worst Performing Large-Cap Stocks in February 2023",
        "image": "https://images.financialmodelingprep.com/news/the-5-best-and-worst-performing-largecap-stocks-in-20230307.jpg",
        "site": "247wallst.com",
        "text": "Investing in large-cap stocks is considered one of the best ways to invest in the stock market.",
        "url": "https://247wallst.com/investing/2023/03/07/the-5-best-and-worst-performing-large-cap-stocks-in-february-2023/"
    },
    {
        "symbol": "SGEN",
        "publishedDate": "2023-03-06 22:55:40",
        "title": "These Are the Top 10 Holdings of David Kim",
        "image": "https://images.financialmodelingprep.com/news/these-are-the-top-10-holdings-of-david-kim-20230306.jpg",
        "site": "247wallst.com",
        "text": "David Kim is the founder and Chief Investment Officer of Ghost Tree Capital. Before founding Ghost Tree Capital in 2013, Kim worked as the portfolio manager at Diamondback Capital (Nov 2006 \u2013 Dec 2012).",
        "url": "https://247wallst.com/investing/2023/03/06/these-are-the-top-10-holdings-of-david-kim/"
    }
]